Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Bevacizumab and daily temozolomide for recurrent glioblastoma

(2011) Annick Desjardins et al.   CANCER

Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure

(2010) C. Lu-Emerson et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab

(2009) Roy G. Torcuator et al.   JOURNAL OF NEURO-ONCOLOGY

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis

(2009) Roy Torcuator et al.   JOURNAL OF NEURO-ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY